Global healthcare company Novo Nordisk wants to give three biotech startups a Golden Ticket, one each year for three years. The Golden Ticket is one year of free access to a scientist and a bench for research at LabCentral, a state-of-the-art biotech innovation lab in Boston. LabCentral is a 70,000 square-foot facility with lab and office space for 60 biotech startups. The center also provides participants with administrative support, laboratory personnel, and other services essential to startup companies.
Novo Nordisk suggests proposals from interested life science start-ups should be for biotech solutions focused on diabetes and related complications, obesity, cardiovascular disease, chronic kidney disease, hemophilia, non-alcoholic steatohepatitis (NASH), or technologies that can apply to those diseases.
Companies that wish to apply for a Golden Ticket are encouraged to review the terms and conditions and apply by Friday, September 20, 2019. Novo Nordisk will select an unspecified number of companies to present proposals later this fall and announce the winner at a Boston biotech and academic community ceremony.
